|Mr. Jes Trygved||Chief Exec. Officer||N/A||N/A||1973|
|Benedikte Bandak||Head of Clinical Devel. & Operations||N/A||N/A||N/A|
|Martin Juhl||Head of CMC, Device Devel. & Operations||N/A||N/A||N/A|
|Louise Bak||Head of Regulatory Affairs||N/A||N/A||N/A|
|Etienne Adriansen||Head of Bus. Devel.||N/A||N/A||N/A|
Cessatech A/S engages in identifying and developing drugs for the treatment of medical unmet need in children in Denmark. The company's lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for magnetic resonance imaging scanning; and CT003, a local anesthetic gel for open wounds. The company was incorporated in 2020 and is based in Copenhagen, Denmark.
Cessatech A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.